^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects
Excerpt:
Patients must have Clinical Laboratory Improvement Act (CLIA) confirmed presence of a somatic or germline alteration considered pathogenic/likely pathogenic by FM and/or the Genetics Review Panel in one or more of the following genes: BRCA1, BRCA2, ATM, BAP1, FANCF, PALB2, and BRIP1...
Trial ID:
Test:
